Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Fluorouridine" is a non-specific term that can refer to at least two distinct nucleoside analogs: 5-Fluorouridine and 4'-Fluorouridine. 5-Fluorouridine (FUrd) is a pyrimidine nucleoside analog that has been investigated for its anticancer properties. It acts by targeting uridine phosphorylase and is also a metabolite of 5-fluorouracil. Its mechanism of action involves interfering with DNA and RNA synthesis, primarily by inhibiting thymidylate synthase and being incorporated into RNA, leading to cell death in rapidly dividing cancer cells. 4'-Fluorouridine (4'-FlU, EIDD-2749) is a ribonucleoside analog developed as an oral antiviral agent. It demonstrates efficacy against a broad spectrum of RNA viruses, including SARS-CoV-2, Respiratory Syncytial Virus (RSV), avian influenza, and various hemorrhagic fever viruses (such as Nipah, Crimean-Congo, orthohantaviruses, and arenaviruses). Its antiviral mechanism involves inhibiting RNA-dependent RNA polymerase (RdRp), leading to transcriptional stalling and preventing viral replication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluorouridine (Non-specific).